Le Lézard
Classified in: Health
Subjects: LEG, POL, AVO

ADAP Advocacy Association Spearheads National Campaign to Protect Ryan White HIV/AIDS Program


Nearly 100 organizations endorse sign-on letter expressing concerns over S.4395

WASHINGTON, Aug. 15, 2022 /PRNewswire/ -- The ADAP Advocacy Association today submitted a sign-on letter to Congress expressing the HIV Community's collective concerns over the Ryan White PrEP Availability Act (S.4395). The sign-on letter ? which was endorsed by nearly 100 national, state, and local organizations ? is part of a national campaign to protect the Ryan White HIV/AIDS Program (RWHAP), namely opposing efforts to raid the program to fund pre-exposure prophylaxis.

The sign-on letter was sent to Chair and Ranking Member of the Senate Committee on Health, Education, Labor & Pensions (HELP), Chair and Ranking Member of the House Committee on Energy & Commerce (E&C), and the Co-Chairs of the Congressional HIV/AIDS Caucus.

S.4395 is an extremely ill-advised approach to public health and it undermines the commitment made to people living with HIV/AIDS in the United States. For over thirty years, RWHAP has served as the nation's only public health program solely dedicated to providing support and services to people living with HIV/AIDS. Instead, other programs that already exist for prevention services should be strengthened and better funded. A better option to meet the needs of people who would benefit from PrEP, and that is additional HIV prevention funding. This approach would allow patient choice in medicines and support for ancillary services, provider education and outreach. Additionally, HIV prevention funding could be directed to communities that are most in need of prevention medicines and services, thereby providing more equitable access. This approach would also use and could strengthen the existing HIV prevention infrastructure. It also preserves services and supports for the people who need them the most...people living with HIV/AIDS.

Read the sign-on letter expressing the HIV Community's concerns over S.4395: https://tinyurl.com/dydtr6vs.

To learn more about the ADAP Advocacy Association, AIDS Drug Assistance Programs, or S.4395, please email [email protected].

About the ADAP Advocacy Association: The ADAP Advocacy Association mission is to promote and enhance the AIDS Drug Assistance Programs (ADAPs) and improves access to care for persons living with HIV/AIDS. aaa+® works with advocates, community, health care, government, patients, pharmaceutical companies and other stakeholders to raise awareness, offer patient educational programs, and foster greater community collaboration.

This press release was issued through 24-7PressRelease.com. For further information, visit http://www.24-7pressrelease.com.

SOURCE ADAP Advocacy Association


These press releases may also interest you

at 09:05
Smart Meter, the leading supplier of Cellular Remote Patient Monitoring (RPM)tm solutions, has introduced a new version of the iGlucose, its patented cellular-connected glucose meter used by over 200,000 people with diabetes since 2019. The...

at 09:00
Today, the Honourable Gary Anandasangaree, Minister of Crown-Indigenous Relations; the Honourable Patty Hajdu, Minister of Indigenous Services and Minister responsible for FedNor; the Honourable Dan Vandal, Minister of Northern Affairs; and the...

at 08:05
GE HealthCare today unveiled SIGNA MAGNUS, an FDA 510(k) pending head-only magnetic resonance (MR) scanner designed to explore advancements in neuroscience, which have been restricted by the performance limitations of conventional whole-body MR...

at 07:00
To mark National Hospice Palliative Care Week, the Quebec Coalition for Palliative Care Access (the Coalition) is proud to celebrate the positive impact of palliative care on the well-being of people with life-limiting illness. Palliative care is...

at 06:00
A native born and trained Brazilian oncologist is in the forefront of a new era in the treatment of cancer patients with cutting edge proton therapy medical technology developed in Israel by P-Cure. "It is my dream to be able to bring the P-Cure...

4 mai 2024
UroGen Pharma Ltd. , a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced results from a new analysis of the ATLAS trial, which estimates using Kaplan Meier...



News published on and distributed by: